In this study, the IGF-1 receptor inhibitor AG1024 increased the response of resistant cancer cells to docetaxel and decreased the expression of TUBB2B, highlighting the potential of targeting the IGF-1 axis as a novel therapeutic strategy. The gene discussed is IGF1; the disease is cancer.